Study details
Enrolling now
Imaging SV2A in Mood Disorders
Yale University
NCT IDNCT02734602ClinicalTrials.gov data as of Apr 2026
Target enrollment
130
Study length
about 11 years
Ages
18–70
Locations
1 site in CT
About this study
Researchers are testing whether ketamine can reverse synaptic loss in the brain of people with depression or PTSD. The trial will involve imaging and PET scans to measure SV2A density, a protein related to synaptic function.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Ketamine
DrugKetamine
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low11%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
ketamine (NMDA receptor antagonist; induces dissociative anesthesia and analgesia)
Body systems
Psychiatry / Mental Health